ANSWER: Whether stents are beneficial in people with stable coronary artery disease remains somewhat controversial. Although ...

Coronary artery disease (CAD) is common in patients with cirrhosis, but cirrhosis itself is not significantly associated with an increased CAD risk.

Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Coronary artery disease (CAD) is common in patients with cirrhosis, but cirrhosis itself is not significantly associated with an increased CAD risk, according to a review published online Nov. 21 ...

XyloCor Therapeutics, Inc., ("XyloCor"), a clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of a $67.5 million Series ...

PR-15 is under clinical development by advanceCor and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

This surge is primarily driven by the growing demand for minimally invasive procedures to treat cardiovascular diseases, which are on ...

The following is a summary of “Impact of frailty on outcomes following coronary artery bypass grafting: a systematic review ...

PRNewswire Tampa Florida [US] January 7 Concept Medical Inc a global leader in innovative drug-delivery technology proudly ...

Surviving a severe case of COVID-19 may be just as dangerous for your heart as having cardiovascular disease - even if you were perfectly healthy before infection.